Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857415 | 0.79 | EPHX2 (0.58) | EPHX2GAAL3MBTL1TSHRALDH1A1 | |
| SCHEMBL17557665 | 0.79 | CTSK (0.50) | EPHX2GAA | |
| SCHEMBL17591906 | 0.78 | MEN1 (0.43) | EPHX2GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL13003444 | 0.77 | CNR1 (0.38) | EPHX2GAA | |
| SCHEMBL7310251 | 0.77 | TSHR (0.51) | GAAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL2937346 | 0.77 | TP53 (0.58) | EPHX2L3MBTL1TSHRALDH1A1POLB | |
| SCHEMBL27033460 | 0.77 | EPHX2 (0.58) | EPHX2MEN1KMT2AL3MBTL1TSHR | |
| SCHEMBL18547134 | 0.76 | ALDH1A1 (0.42) | EPHX2L3MBTL1ALDH1A1 | |
| SCHEMBL20482733 | 0.75 | TSHR (0.44) | EPHX2GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL2680036 | 0.74 | CNR1 (0.33) | EPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421864-B1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2421864-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122272-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | EPHX2 1215/4885GAA 3828/4885MEN1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.